RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages

Author(s): Kokkola R, Andersson A, Mullins G, Östberg T, Treutiger CJ, et al.

Abstract

High-mobility group box chromosomal protein 1 (HMGB1) is a protein with both intranuclear functions and extracellular cytokine-like effects. In this report, we study possible candidate receptors for HMGB1 on macrophages (Mφ) and define pathways activated by HMGB1 binding. Bone marrow Mφ were prepared from Dark Agouti (DA) rats and stimulated in vitro with HMGB1. The kinetics of tumour necrosis factor (TNF) production, NO production, activation of p38 mitogen-activated protein kinase (MAPK), p44/42 MAPK- and SAPK/JNK-signalling pathways, nuclear translocation of nuclear factor kappa B (NF-κB) and HMGB1-induced upregulation of major histocompatibility complex (MHC) class II and CD86 were analysed. Mφ from interleukin (IL)-1 receptor type I–/–, Toll-like receptor 2 (TLR2–/–) and RAGE–/– mice were used to investigate the role of these receptors in HMGB1 signalling. HMGB1 induced TNF and NO production by Mφ, phosphorylation of all investigated MAP kinase pathways and NF-κB translocation, and expression of MHC class II was increased. Mφ from RAGE–/– mice produced significantly lower amounts of TNF, IL-1β and IL-6, while IL-1RI–/– and TLR2–/– Mφ produced cytokine levels comparable with wildtype controls in response to HMGB1 stimulation. We conclude that HMGB1 has the potential to induce a proinflammatory phenotype in Mφ, with RAGE as the major activation-inducing receptor.

Similar Articles

Role of altered expression of HLA class I molecules in cancer progression

Author(s): Aptsiauri N, Cabrera T, Mendez R, Garcia-Lor A, Ruiz-Cabello F, et al.

β-Arrestin-dependent, G protein-independent ERK1/2 activation by the 2-adrenergic receptor

Author(s): Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, et al.

Human T cell responses against melanoma

Author(s): Boon T, Coulie PG, Van Den Eynde BJ, Van Der Bruggen P

Mutations in GNA11 in Uveal Melanoma

Author(s): Van Raamsdonk C, Griewank K, Michelle B, Crosby MB, Garrido MC, et al.

Cohesin‐SA1 deficiency drives aneuploidy and tumourigenesis in mice due to impaired replication of telomeres

Author(s): Remeseiro S, Cuadrado A, Carretero M, Martínez P, Drosopoulos WC, et al.

MDM4 is a key therapeutic target in cutaneous melanoma

Author(s): Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele A, et al.

Epithelial–mesenchymal transition in cancer development and its clinical significance

Author(s): Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, et al.

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

Author(s): Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, et al.

The epithelial-mesenchymal transition generates cells with properties of stem cells

Author(s): Mani A, Guo W, Liao MJ, Eaton E, Ayyanan A, et al.

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

Author(s): Azuma T, Yao S, Zhu G, Flies A, Flies S, et al.

Breast cancer version 3

Author(s): Gradishar W, Anderson B, Blair S, Burstein H, Cyr A, et al.

In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas

Author(s): Schalper K, Velcheti V, Carvajal D, Wimberly H, Brown J, et al.

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

Author(s): Muenst S, Schaerli AR, Gao F, Däster S, Trella E, et al.

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

Author(s): Twyman-Saint VC, Rech AJ, Maity A, Rengan R, Pauken KE, et al.

Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion

Author(s): Cooke NM, Spillane CD, Sheils O, O’Leary J, Kenny D

Immune cell promotion of metastasis

Author(s): Kitamura T, Qian BZ, Pollard JW

FOXP3+regulatory T cells affect the development and progression of hepatocarcinogenesis

Author(s): Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, et al.

Methylation not a frequent “second hit” in tumors with germline BRCA mutations

Author(s): Dworkin AM, Spearman A, Tseng S, Sweet K, Amanda AE

Epithelial-mesenchymal transitions in development and disease

Author(s): Thiery JP, Acloque H, Huang R, Nieto A

Molecular biomarker in prostate cancer: The role of CpG island hypermethylation

Author(s): Bastian P, Yegnasubramanian S, Palapattu G, Rogers C, Lin X, et al.

Molecular epigenetics and genetics in neuro-oncology

Author(s): Nagarajan R, Costello J